Trials / Withdrawn
WithdrawnNCT05381974
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This open-label fMRI study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with treatment-resistant major depressive disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Psilocybin | Open-Label |
Timeline
- Start date
- 2022-09-15
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
- First posted
- 2022-05-19
- Last updated
- 2024-01-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05381974. Inclusion in this directory is not an endorsement.